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A 76 year old woman reports recurrent urinary frequency,
dysuria, and malodorous urine. No bacterial growth has been
identified on two midstream urine samples, though empirical
treatment with antibiotics has improved her symptoms. After
three months, an episode of visible haematuria prompts referral
and a transitional cell carcinoma of the bladder is diagnosed.
What are the types of bladder cancer?
In developed countries 90% of bladder cancers are transitional
cell carcinomas; squamous cell carcinomas (SCC) make up
most of the remainder.1 2 In endemic areas, squamous cell
carcinoma related to schistosomiasis accounts for 70% of cases.1
Around 20% are muscle invasive at diagnosis and are associated
with a significantly poorer prognosis.3 The major risk factor is
smoking, though chronic infection, radiotherapy, and (before
regulation) industrial dyes have been implicated.2 4
Why is it missed?
Although bladder cancer is more common in men, women
experience more delays: the English National Audit of Cancer
Diagnosis in Primary Care (2009-10) estimated that annually
435 more women than men with bladder cancer experience a
delay in diagnosis, but there are few data fromUK primary care
to explain this.6 With no effective screening tool for bladder
cancer, it is usually diagnosed symptomatically, with haematuria
being the most common presenting symptom for both sexes in
primary care (likelihood ratio 59, 95% confidence interval 51
to 57).3 7 The likelihood ratio summarises howmany times more
(or less) likely patients with bladder cancer are to have a
particular feature than patients without bladder cancer. A ratio
over 10 (or under 0.1) is considered to provide strong evidence
to rule in (or rule out) bladder cancer.
A study of outpatient haematuria claims for 7649 patients aged
>65 in the United States (female:male 1:2.43) also described a
delay in diagnosis after presentation in women. The mean time
to diagnosis was 85.5 days in women (95% confidence interval
81.3 to 89.4) compared with 73.6 days (71.2 to 76.1) in men
(P<0.001). This difference persisted over time; women were
26% more likely to experience delay at three months after the
initial claim, 16% at six months, and 23% at nine months.8
During investigations, women undergo more urinalyses (1.39
v 1.19, P<0.001) and urine cultures (0.83 v 0.53, P<0.001) and
receive more diagnoses of urinary tract infections (odds ratio
2.32, 95% confidence interval 2.07 to 2.59; P<0.001) and more
antibiotics (40.1% v 35.4%, P<0.001), yet are less likely to
undergo bladder imaging (odds ratio 0.80, 0.71 to 0.89;
P<0.001).8
Bladder cancer is also associated with voiding disorders and
abdominal pain, but European data from primary care and
gynaecology report that women with these complaints are more
likely to be treated empirically, with treatments given without
further evaluation in 47% of women compared with 19% of
men in the year before diagnosis (P<0.05).9
Although these data are not wholly derived from primary care,
it is implicit that prolonged investigation and treatment for
urinary tract infections over repeated consultations (without
confirmation of symptom resolution) is more of a problem in
women.
Why does this matter?
Although there are recognised sex differences in tumour biology,
bladder anatomy, and environmental and hormonal exposures
that contribute to differential outcomes, there is some evidence
of a correlation between delay in primary care and worsening
prognosis.10-12
Correspondence to: B D Nicholson brian.nicholson@phc.ox.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g2171 doi: 10.1136/bmj.g2171 (Published 31 March 2014) Page 1 of 3
Practice
PRACTICE
How common is bladder cancer in women?
• Bladder cancer is the seventh most common cancer in the United Kingdom and the 11th most common in women5
• In 2010 there were 10 324 new diagnoses of bladder cancer in the UK, with a female to male ratio of 2:5, accounting for 4900 deaths5
• An average general practice expects to see one new diagnosis of female bladder cancer every 3.5 years
• The average age at diagnosis is 715
Prospective data from the UK for 1537 cases of bladder cancer
(1340 detailing stage, and 633 both stage and cause of death)
showed an association between longer delay between start of
symptoms and GP referral and a 5% increased incidence of
muscle invasive bladder cancer (pT2-4) (P=0.04).12 Five year
survival was significantly worse for women presenting with
muscle invasive disease (P<0.001).12 While the report did not
distinguish between patient delay and GP delay, longer delay
before referral (>14 v <14 days) resulted in an increased risk of
death (hazard ratio 1.19, 95% confidence interval 1.01 to 1.42;
P=0.04) and 5% poorer five year survival (P=0.02).12 Patients
with delay in their referral pathway seem to havemore advanced
disease, with poorer outcomes; arguably, they warrant the most
expedient intervention compared with other groups.
How is it diagnosed?
Clinical features
The National Institute for Health and Care Excellence (NICE)
recommends urgent urology referral for adults with visible
haematuria in the absence of urinary tract infection or in the
presence of recurrent or persistent urinary tract infection in those
aged >40; for unexplained microscopic haematuria in those
aged >50; and for an abdominal mass arising from the bladder;
and a non-urgent referral in those aged <50 with unexplained
microscopic haematuria without raised creatinine concentration
or proteinuria.13
Most studies in primary care have examined haematuria alone,
though two—which both used pre-existing medical
records—reported a broad range of symptoms associated with
bladder cancer per se3 and with urinary tract cancer
collectively.14Most patients presented with painless haematuria,
voiding symptoms, or a combination of the two.
Haematuria
The case-control study using electronic medical records from
UK primary care showed that painless macroscopic haematuria
is the strongest predictor of bladder cancer in primary care (odds
ratio 34, 95% confidence interval 29 to 41), with a positive
predictive value in patients aged over 60 of 3.9% (3.5% to
4.6%).3 The national audit showed that two thirds of patients
had haematuria recorded as their primary symptom in primary
care6; though the prospective secondary care study showed that
90% of referred patients had haematuria (the severity of which
did not correlate with disease severity); 25% of those referred
will have transitional cell carcinoma of the bladder.6 12
Less specific symptoms
The case-control study also showed that the commonly
encountered symptoms of dysuria (odds ratio 4.1, 95%
confidence interval 3.4 to 5.0), abdominal pain (2.0, 1.6 to 2.4),
and constipation (1.5, 1.2 to 1.9), and a diagnosis of urinary
tract infection (2.2, 2.0 to 2.5) are associated with bladder cancer
but with much lower predictive values.3 Patients with more
advanced disease might present with pelvic pain or urinary
obstruction. In these patients, a mass might be palpable.
Importantly, re-attendance with persistent symptoms is
associated with an increased risk of cancer.
Investigations
Non-specific
Urinalysis is accurate in detecting haematuria, proteinuria,
nitrites, or leucocyte esterase, with subsequent microscopy and
culture to confirm infection. Although three blood tests with
abnormal results—raised white cell count, raised inflammatory
markers, and raised creatinine—are associated with bladder
cancer, these tests alone cannot be used to rule out the condition.3
The main role of urine cytology is in follow-up of patients with
carcinoma in situ, rather than in the diagnosis of cancer. No
primary care studies have reported its performance
characteristics in diagnosis, but sensitivity is only 38% in
secondary care and probably lower in primary care.15
Definitive
Flexible cystoscopy is the mainstay of investigation and is
performed on a day case basis. It allows direct visualisation and
biopsy of bladder abnormalities, but not treatment.
Ultrasongraphy of the renal tract is often added as the symptoms
of bladder and renal cancer overlap.6 For patients with bladder
cancer, staging might require computerised tomography and
isotope bone scanning; positron emission tomography is
increasingly used in specialist centres.
How is it managed?
Initial treatment depends on staging; less advanced disease is
resected transurethrally (TURBT). Patients with low risk disease
are offered cystoscopic surveillance, while recurrent low risk
disease or intermediate/high risk disease can require intravesical
chemotherapy or immunotherapy (with BCG). More advanced
disease can require cystectomy or radical radiotherapy, with or
without neo-adjuvant chemotherapy.2
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Key points
Women with bladder cancer are more likely to present with muscle invasive disease, partly associated with delays in diagnosis in primary
care
Haematuria is the most highly predictive symptom of bladder cancer, and appropriate investigation and referral should not be delayed
If women are treated for presumed urinary tract infection, active follow-up should ensure that symptoms have settled with treatment with
antibiotics
Symptomatic women aged over 50 without confirmation of infection on urinalysis or microscopy and culture should be referred for further
assessment to identify a definitive cause
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